{"id":7720,"date":"2025-06-27T17:09:03","date_gmt":"2025-06-27T14:09:03","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7720"},"modified":"2025-06-27T17:09:03","modified_gmt":"2025-06-27T14:09:03","slug":"sudden-vision-loss-as-a-cardiovascular-red-flag","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/sudden-vision-loss-as-a-cardiovascular-red-flag\/","title":{"rendered":"Sudden Vision Loss as a Cardiovascular Red Flag"},"content":{"rendered":"
Sudden Vision Loss as a Cardiovascular Red Flag<\/div>\n
Source: Medscape.Published June 24, 2025<\/div>\n
<\/div>\n
Key Points Summary:<\/div>\n
1. Vascular Causes of Vision Loss:<\/span><\/div>\n
\u2022 Retinal artery or vein occlusion is a major cause of sudden, painless vision loss.<\/span><\/div>\n
\u2022 These are ophthalmologic emergencies and often linked to systemic cardiovascular risk factors:<\/span><\/div>\n
hypertension, diabetes, dyslipidemia, coronary and peripheral vascular disease.<\/div>\n
2. Atrial Fibrillation (AF) and Vision Risk:<\/span><\/div>\n
\u2022 AF is associated with central retinal artery occlusion, which can lead to irreversible vision loss.<\/span><\/div>\n
\u2022 A Medicare study (1M+ patients \u226566 y\/o) found a possible link between AF and retinal stroke.<\/span><\/div>\n
\u2022 Cardiologists should actively screen for undiagnosed AF to mitigate thromboembolic risk.<\/span><\/div>\n
3. Antithrombotic Therapy Considerations:<\/span><\/div>\n
\u2022 Anticoagulants may be used in selected retinal vein occlusion cases but carry hemorrhagic risk.<\/span><\/div>\n
\u2022 Antiplatelets show limited benefit in visual recovery.<\/span><\/div>\n
4. Multimorbidity and Risk:<\/span><\/div>\n
\u2022 Patients often have metabolic, renal, hepatic, hematologic, and other disorders (e.g., OSA, glaucoma).<\/span><\/div>\n
\u2022 These comorbidities increase cardiovascular risk and impact visual prognosis.<\/span><\/div>\n
5. Blood Pressure Control:<\/span><\/div>\n
\u2022 Optimal BP control is crucial to preserve ocular health.<\/span><\/div>\n
\u2022 Both high BP and excessive BP variability impair the blood-retina barrier and perfusion regulation.<\/span><\/div>\n
\u2022 Contributes to other ocular conditions like glaucoma, cataracts, macular degeneration.<\/span><\/div>\n
6. Semaglutide Safety Signal:<\/span><\/div>\n
\u2022 Emerging concern about semaglutide use and nonarteritic anterior ischemic optic neuropathy (NAION).<\/span><\/div>\n
\u2022 Risk noted in type 2 diabetics and obese patients; study limitations acknowledged, but vigilance advised.<\/span><\/div>\n
<\/div>\n
Clinical Implications for Cardiologists:<\/div>\n
\u2022 Be alert to complaints of vision changes \u2014 they may indicate vascular pathology.<\/span><\/div>\n
\u2022 Collaborate closely with ophthalmologists.<\/span><\/div>\n
\u2022 Control cardiovascular and metabolic comorbidities to prevent both ocular and systemic complications.<\/span><\/div>\n
<\/div>\n
Management of Central Retinal Artery Occlusion (A Scientific Statement From the AHA 2021) :<\/div>\n
Key Points (as listed in the statement):<\/span><\/div>\n
<\/div>\n
1. CRAO is an ophthalmic emergency\u2014equated with an acute ischemic stroke (\u201ceye\u2011stroke\u201d); immediate triage to a stroke-ready hospital is essential.<\/span><\/div>\n
2. IV thrombolysis (tPA) can be considered if administered within 4.5 hours of symptom onset.<\/span><\/div>\n
3. Implementation of \u201ceye\u2011stroke\u201d protocols across healthcare systems is recommended to reduce treatment delays and improve outcomes.<\/span><\/div>\n
4. Increased awareness among the public and providers is critical: acute monocular vision loss should be treated with the same urgency as cerebral stroke or TIA.<\/span><\/div>\n
5. Systemic evaluation of CRAO patients should include assessment for carotid stenosis, atrial fibrillation, hypertension, diabetes, dyslipidemia, and smoking.<\/span><\/div>\n
<\/div>\n
The AHA\/ASA guidance regarding antiplatelet therapy in CRAO, compiled from the scientific statement and expert reviews:<\/div>\n
Antiplatelet Recommendations in CRAO (Secondary Prevention)<\/div>\n
1. CRAO = Stroke Equivalent<\/span><\/div>\n
\u2022 AHA considers CRAO analogous to acute cerebral ischemic events, warranting urgent stroke-focused evaluation and management\u00a0 \u00a0.<\/span><\/div>\n
2. Initiate Antiplatelet Therapy if No Anticoagulation Indication<\/span><\/div>\n
\u2022 For patients without a cardioembolic source (e.g., atrial fibrillation) or surgical indication, antiplatelet therapy is reasonable\u00a0 .<\/span><\/div>\n
3. Regimen: Dual \u2192 Single Antiplatelet<\/span><\/div>\n
\u2022 If no contraindications, start an initial 21-day course of dual antiplatelet therapy (DAPT), typically:<\/span><\/div>\n
\u2022 Aspirin 81\u202fmg daily + Clopidogrel 75\u202fmg daily, beginning within 24 hours of symptom onset\u00a0 \u00a0 .<\/span><\/div>\n
\u2022 Thereafter, continue long-term single antiplatelet therapy (SAPT) with either:<\/span><\/div>\n
\u2022 Aspirin 81\u202fmg daily, or<\/span><\/div>\n
\u2022 Clopidogrel 75\u202fmg daily .<\/span><\/div>\n
4. Implement Within 24 Hours<\/span><\/div>\n
\u2022 The 21-day DAPT course should begin within the first day post-CRAO, mirroring TIA\/stroke protocols<\/span><\/div>\n
<\/div>\n
https:\/\/click.mail.medscape.com\/?qs=6b49d08b84c552922669efae72dd2738b59334471588d26f506ae3075fc8955d4aa04db4941159b072381a5873029f324fdf337450606c5c559de8a585afcaff<\/div>\n
<\/div>\n
https:\/\/www.ahajournals.org\/doi\/10.1161\/STR.0000000000000366<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Sudden Vision Loss as a Cardiovascular Red Flag Source: Medscape.Published June 24, 2025 Key Points Summary: 1. Vascular Causes of Vision Loss: \u2022 Retinal artery or vein occlusion is a major cause of sudden, painless vision loss. \u2022 These are ophthalmologic emergencies and often linked to systemic cardiovascular risk factors: hypertension, diabetes, dyslipidemia, coronary and […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7720","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7720","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7720"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7720\/revisions"}],"predecessor-version":[{"id":7724,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7720\/revisions\/7724"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7720"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7720"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7720"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}